PMC:7228307 / 25526-25797
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
446 | 81-88 | Gene | denotes | FcγRIII | Gene:2214 |
447 | 111-118 | Gene | denotes | FcγRIIa | Gene:2212 |
448 | 123-128 | Gene | denotes | FcγRI | Gene:2214 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T255 | 162-166 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T486 | 81-83 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T487 | 111-113 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T488 | 123-125 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T489 | 162-166 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T132 | 126-128 | Chemical | denotes | RI | http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T151 | 162-166 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
446 | 81-88 | Gene | denotes | FcγRIII | Gene:2214 |
447 | 111-118 | Gene | denotes | FcγRIIa | Gene:2212 |
448 | 123-128 | Gene | denotes | FcγRI | Gene:2214 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T148 | 0-271 | Sentence | denotes | The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later. |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T254 | 162-166 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sample-PD-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 265-270 | http://purl.obolibrary.org/obo/MAT_0000488 | denotes | later |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T67 | 162-174 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | cell killing |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T67 | 162-174 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | cell killing |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T67 | 162-174 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | cell killing |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T148 | 0-271 | Sentence | denotes | The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later. |